Equity Commonwealth (NYSE:EQC)
Equity Commonwealth (NYSE:EQC), ended its previous trading session at $27.09 showing a gain of 0.0199999999999996 or 0.07 percent with respect to the price of $27.07 when stock market opened. The company traded 592543 shares over the course of the trading day. Giving the average volume of 867.05 Million over the course of 3 consecutive months. Which signifies a pretty good change over the time with its shares outstanding of 121.66 Million.
Equity Commonwealth (NYSE:EQC) is currently trading lower than its price target which is set to $32.25 by the analyst. The stock is -12.53% Below its 1-Year High which is $30.97. EQC has a difference of 11.1% from its 1 year low which stands at $24.38. The company is currently rated by analyst who are keeping a close eye on the stock as 2. Where 1 means Buy, 2.5 meaning Hold and 5 as Sell.
Equity Commonwealth (NYSE:EQC) Performance Snapshot
The stock performed exceptionally bad in the previous week which depicts an decrease of -0.81 percent in the shares price. The company added about 0.97% in its share price over 1-Month. While taking about the performance of the stock over 1-year interval is -1.84 Percent. EQC currently shows -6.53% as its year to date performance.
Equity Commonwealth (NYSE:EQC) Price Insight
The stock needs to grow about $5.16 to reach its price target. In order to seek the stock’s directional movements, 20-Days, 50 Days and 200-Days moving averages are 0.97%, 0.12% and -3.94 percent respectively. The stock trades about 1.27 percent of its Float giving its total shares Outstanding are 121.66 Million. EQC lost about -9.46 percent in 6 months showing its Average True Range of 0.46. The company currently has a RSI and Beta of 51.37 and 0.25.
While talking about Equity Commonwealth (NYSE:EQC) valuation ratios, the stock trades with a P/S and P/B of 37.25 and 0.93 which is significantly better and attractive as compared to its peers.
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA)
Performance Indicators of Dova Pharmaceuticals, Inc. (NASDAQ:DOVA)
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) Analytical Review